| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Collaboration revenue | 11,082 | - |
| Personnel-related | 30,342 | - |
| Preclinical and manufacturing | 12,910 | - |
| Facilities-related | 16,392 | - |
| Stock-based compensation | 5,681 | - |
| Lab supplies | 2,802 | - |
| Consulting and professional services | 9,872 | - |
| Loss on lease termination | 23,838 | - |
| Other | 3,151 | - |
| Total operating expenses | 57,312 | - |
| Loss from operations | -46,230 | - |
| Other income and interest income, net | 4,985 | - |
| Net loss | -41,245 | -35,725 |
| Loss on lease termination | 23,838 | -1,652 |
| Stock-based compensation expense | 5,681 | 3,704 |
| Other | - | -139 |
| Depreciation and amortization expense | 3,674 | 2,270 |
| Accretion of discount on marketable securities, net | 2,577 | 1,881 |
| Losses on property and equipment, net | -1,911 | - |
| Collaboration receivable | -833 | -968 |
| Prepaid expenses and other current assets | -3,914 | -2,732 |
| Operating lease right-of-use assets | -2,881 | -1,895 |
| Other noncurrent assets | -539 | -472 |
| Accounts payable | 725 | 893 |
| Accrued expenses and other current liabilities | 3,201 | -3,457 |
| Deferred revenue | -9,042 | -7,840 |
| Other noncurrent liabilities | -223 | -223 |
| Operating lease liabilities | -44,302 | -10,509 |
| Net cash used in operating activities | -97,868 | -45,188 |
| Purchases of property and equipment | 705 | 705 |
| Proceeds from sale of property and equipment | 475 | 234 |
| Purchases of marketable securities | 66,334 | 51,621 |
| Maturities of marketable securities | 110,000 | 70,000 |
| Net cash provided by (used in) investing activities | 43,436 | 17,908 |
| Proceeds from exercise of stock options and espp, net | 81 | 81 |
| Tax withholding payments related to net share settlements of restricted stock units | 10 | 8 |
| Net cash used in financing activities | 71 | 73 |
| Net decrease in cash, cash equivalents and restricted cash | -54,361 | -27,207 |
| Cash and cash equivalents at beginning of period | 78,453 | - |
| Cash and cash equivalents at end of period | 24,092 | - |
Generation Bio Co. (GBIO)
Generation Bio Co. (GBIO)